Mergers and acquisitions is the module where students discover how much finance depends on judgement. The valuation maths is standard — DCF, multiples, precedent transactions — but the assumptions that drive it are contested. Synergy estimates come from management. Integration costs get underestimated. Premium size is decided in a negotiation the model can only frame. And the empirical record on whether M&A creates shareholder value is genuinely uncomfortable — most deals do not.
This guide takes you through what an M&A assignment actually tests, the four valuation methods you need, a full worked example on a target acquisition with synergy quantification, an accretion/dilution analysis for the same deal, and the analytical moves that lift an M&A assignment from "shows the maths" to a defensible commercial recommendation. If your brief is a deal analysis, a case study, or a strategic evaluation, the pattern below applies.
What an M&A Assignment Actually Tests
M&A assignments test four connected skills. The strongest answers hit all four; competent answers usually get the first two right and drop marks on the third and fourth.
- Target valuation — Can you value the target using two or more of the standard methods (DCF, comparable companies, precedent transactions, LBO analysis) and present a defensible range rather than a point estimate?
- Synergy quantification — Can you separate revenue synergies from cost synergies, estimate their steady-state value, discount them appropriately, and subtract one-off integration costs?
- Deal structure & accretion/dilution — Can you decide whether cash or stock is the right currency, and compute whether the deal is accretive or dilutive to acquirer EPS?
- Value creation judgement — Can you compare synergies to the premium paid, engage with why most M&A deals destroy value, and reach a defensible recommendation? This is where First-class answers separate.
Read the brief carefully: "Evaluate the acquisition of X by Y" is a full deal analysis. "Compute the fair value of X" is target valuation only. "Should Y proceed with the acquisition?" is a recommendation-focused brief where the maths supports a commercial call. The valuation method(s) required, the depth of synergy analysis, and the weight of the recommendation all follow from which of these framings applies.
Deal Types and Strategic Rationale
Before valuing anything, most M&A assignments ask you to identify the type of deal and its strategic rationale. Three categories dominate:
| Deal Type | What It Is | Standard Rationale |
|---|---|---|
| Horizontal | Acquirer buys a company in the same industry and at the same stage of the value chain. | Market share consolidation, cost synergies through shared overhead and scale, pricing power. Highest cost-synergy potential. |
| Vertical | Acquirer buys upstream (supplier) or downstream (distributor/customer) in its own value chain. | Supply chain security, margin capture, operational integration. Cost synergies more modest; strategic control more material. |
| Conglomerate | Acquirer buys a company in an unrelated industry. | Diversification of earnings, capital reallocation, entry to new markets. Synergies typically limited; empirical performance mixed. |
The deal type shapes what synergies are realistically achievable. Horizontal deals justify aggressive cost synergy assumptions; conglomerate deals do not, and pretending they do is exactly how the maths detaches from reality.
The Four Valuation Methods You'll Use
A serious M&A analysis triangulates across two or more valuation methods. Each captures something the others miss.
| Method | How It Works | What It Tells You |
|---|---|---|
| DCF (intrinsic value) | Forecast free cash flows, discount at WACC, add terminal value. | Standalone fair value under your assumptions. Anchor for the analysis. |
| Comparable companies | Apply industry multiples (EV/EBITDA, P/E, EV/Revenue) from listed peers. | What the market is currently paying for similar businesses. Sanity check on DCF. |
| Precedent transactions | Apply multiples from recent M&A deals in the same sector. | What acquirers have paid — includes control premiums. Directly relevant to bid-setting. |
| LBO analysis | Solve for the price at which a financial buyer earns a target IRR (typically 20%+). | Valuation floor from the private equity bid perspective. Not always applicable. |
Building all four methods for one target typically produces a valuation range where the low end is the LBO floor and the high end is the precedent transaction ceiling. The DCF and comparable companies figures usually sit in between. The financial modelling guide covers the DCF craft in depth; here we treat it as an input and focus on the M&A-specific steps that follow.
A Worked Example — Orion Industries Acquires Cassini Precision
The scenario below is constructed for demonstration; the analytical moves apply to any acquisition brief.
Standalone net income: £200m
Shares outstanding: 400m
Share price: £15.00
Market cap: £6,000m; P/E: 30×
Target — Cassini Precision Ltd (specialist manufacturer)
Revenue: £400m; EBITDA margin 18% → EBITDA £72m
Net income: £45m
Pre-deal fair value estimate (DCF): £650m
Proposed deal
Purchase price (enterprise value): £800m (all-stock)
Implied EV/EBITDA multiple: 11.1×
Control premium over fair value: £150m (23.1%)
Deal type: Horizontal (same industrial sector)
Step 1 — Quantifying Synergies
Synergies are the reason the acquirer is willing to pay a premium above fair value. Separate them by type before valuing them — the two categories behave very differently.
— shared overhead, procurement, plant rationalisation
Revenue synergies (annual, steady-state): £15m
— cross-selling into Orion's distribution network
Total annual synergies: £45m (pre-tax)
Tax rate: 25%
Discount rate (Orion's WACC): 9%
Steady-state assumed achieved from Year 3
One-off integration costs: £60m (mainly Year 1)
Perpetuity value at end of Y2 = £33.75m ÷ 0.09 = £375m
PV of perpetuity (discounted 2 years) = £375m ÷ (1.09)² = £315.6m
Less integration costs (Y1): £60m
Net PV of synergies = £315.6m − £60m ≈ £256m
Interpretation: The £256m net PV is what the combined entity is theoretically worth more than the sum of its parts. Two heavy caveats: this figure assumes cost synergies are fully realised (empirically, they are — on average — but revenue synergies typically underdeliver by 30–50%), and it assumes integration costs are contained at £60m (real deals routinely overshoot by 20–40%). A First-class answer applies a haircut of at least 20–30% to the headline synergy PV to acknowledge implementation risk.
Step 2 — Accretion/Dilution Analysis
In an all-stock deal, the acquirer issues new shares to the target's owners. Whether combined earnings per share end up higher (accretive) or lower (dilutive) than standalone EPS is the first question the acquirer's board will ask.
= £800m ÷ £15.00
= 53.3m new shares
New total shares outstanding = 400m + 53.3m = 453.3m
Year 1 synergies (pre-tax): £45m × 50% = £22.5m
After-tax: £22.5m × (1 − 0.25) = £16.9m
Combined NI = Orion NI + Cassini NI + Y1 synergies
= £200m + £45m + £16.9m
= £261.9m
New EPS = £261.9m ÷ 453.3m = £0.578
Change: (£0.578 − £0.500) ÷ £0.500 = +15.5% ACCRETIVE
Interpretation: The deal is accretive to Orion's Year 1 EPS by 15.5%. The mechanical reason is clear: Cassini's implied P/E based on net income is £800m ÷ £45m = 17.8×, well below Orion's 30× — so Orion is buying earnings at a lower multiple than it trades at, which mathematically boosts combined EPS even before any synergies. The synergies amplify the effect. The rule of thumb: in a stock deal, when target P/E is below acquirer P/E, the deal is structurally accretive; when target P/E is above, it is dilutive and needs meaningful synergies to work.
Accretion is not value creation. A deal can be EPS-accretive and still destroy shareholder value if the premium paid exceeds the synergies. The rest of this analysis exists precisely because the EPS test is a headline check, not a verdict.
M&A assignment deadline closing in?
Our finance specialists build full M&A deal analyses — target valuation, synergy PV, accretion/dilution, recommendation with sensitivity — to your university's marking criteria.
Step 3 — The Honest Test: Do Synergies Exceed the Premium?
This is the single most important calculation in an M&A assignment and the one most often skipped. Value is created for the acquirer only if the present value of synergies exceeds the control premium paid.
Net PV of synergies (computed above) = £256m
Value created for Orion shareholders = £256m − £150m = £106m
Interpretation: On the base-case assumptions, Orion pays £150m above Cassini's standalone fair value and creates £256m of net synergies — a net value creation of £106m for acquirer shareholders. A more cautious framing applies a 25% haircut to the synergy figure to reflect implementation risk: £256m × 0.75 = £192m of risk-adjusted synergies, still comfortably above the £150m premium. The deal passes the value creation test even under the more sceptical assumption. This is the paragraph that lifts an assignment from calculation-driven to genuinely commercial.
The Structure of a Strong M&A Assignment
| Section | What Markers Look For | Word Count (3,000w) |
|---|---|---|
| Executive Summary | Deal, recommendation, key financial figures, principal risks. Written last. | 200–300w |
| Strategic Rationale | Deal type, industry context, why this target and why now. | 400–500w |
| Target Valuation | Two or more methods (DCF + at least one multiple-based). Presented as a range. | 500–700w |
| Synergy Analysis | Cost vs revenue synergies separated. Steady-state value, integration costs, net PV. Sensitivity. | 400–500w |
| Deal Structure & Accretion/Dilution | Cash vs stock rationale. EPS impact. Financing structure implications. | 300–400w |
| Risks & Integration | Integration risk, customer overlap, cultural fit, execution risk. Empirical M&A failure evidence. | 400–500w |
| Recommendation | Proceed / walk away / conditional acceptance, with named conditions and pricing bounds. | 300–400w |
2:2 vs First: The Synergy Scepticism Paragraph
"The synergies from the deal have a present value of £256m. The premium paid is £150m. This means the deal creates £106m of value for Orion's shareholders. The deal is recommended and should proceed."
"The base-case synergy PV of £256m exceeds the £150m premium, implying £106m of value creation — but this figure requires several honest caveats. Empirically, cost synergies tend to be delivered close to plan in horizontal industrial deals, while revenue synergies typically underdeliver by 30–50% (KPMG, 2019). Applying a 40% haircut to the £15m annual revenue synergies and a 10% haircut to the £30m cost synergies reduces net PV to approximately £192m — still above the premium, but with a materially thinner cushion. The academic literature is starker: Moeller, Schlingemann & Stulz (2005) find that acquirers destroyed roughly $220bn of shareholder wealth on large US deals in 1998–2001. Against this baseline, the appropriate recommendation is conditional acceptance: proceed if pre-completion diligence confirms the cost-synergy base is intact and the customer overlap does not exceed 15%; walk away otherwise. The deal is defensible on paper; it is not automatic.
Five Mistakes That Cost Students Marks
Treating accretion as value creation. An EPS-accretive deal can still destroy shareholder value if the premium paid exceeds the synergies. The two tests are separate and both must pass.Fix: Always compute both accretion/dilution and the synergy-vs-premium test. State clearly that they measure different things.
Not separating revenue from cost synergies. The two behave differently: cost synergies are typically delivered close to plan; revenue synergies typically underdeliver by 30–50%. Lumping them together buries the risk.Fix: Report revenue and cost synergies separately. Apply different haircuts in your sensitivity analysis. Explain why the asymmetry matters.
Ignoring integration costs entirely. Headline synergy numbers should never be treated as net figures. Integration costs — restructuring, IT harmonisation, redundancies, advisor fees — are real and material.Fix: Subtract integration costs from your synergy PV explicitly. Typical range: 40–100% of one year's synergies as a one-off cost. Under-estimating this understates deal risk.
Reaching unconditional recommendations on ambiguous deals. "The deal should proceed" without conditions treats a fragile analysis as decisive. Markers reward nuance.Fix: Frame recommendations conditionally. Name the specific diligence findings or price movements that would change the answer. Include a walk-away price.
No reference to the empirical M&A failure literature. The academic consensus is that most M&A destroys value for acquirer shareholders. Not mentioning this signals shallow reading.Fix: Cite one M&A performance study — Moeller, Schlingemann & Stulz (2005), KPMG deal outcome surveys, or Bain & Co M&A reports. Position your specific deal against that base rate. This one reference consistently lifts a grade band.
Frequently Asked Questions
What is an M&A assignment usually asking me to do?
What is the difference between accretion/dilution and value creation?
Cash or stock — how do I decide the deal structure?
How do I quantify synergies credibly?
How do I structure an M&A assignment?
My deadline is close — what should I prioritise on an M&A assignment?
Need Your M&A Assignment Done Right?
Our expert writers deliver full M&A deal analyses — target valuation, synergy quantification, accretion/dilution, and the risk-adjusted recommendation that wins marks. To your university's marking criteria and your exact deadline.
Get Expert Help Today →
